• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Budesonide - Key patent, SPC, and data exclusivity expiry (7 country coverage) Product Image

Budesonide - Key patent, SPC, and data exclusivity expiry (7 country coverage)

  • Published: July 2014
  • Genericsweb Pty Ltd – Ark Patent Intelligence

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Budesonide
Budesonide indications: Treatment of hay-fever, nasal polyposis, inflammatory bowel disease, mild to moderate active Crohn's disease, allergic rhinitis, acute laryngotracheobronchitis and bronchial asthma.
Budesonide innovator: AstraZeneca (Budamax, Entocort, Entocort EC, Pulmicort, Pulmicort Flexhaler, Pulmicort Respules, Pulmicort Turbuhaler, Rhinocort, Rhinocort Aqua, Rhinocort Hayfever, Symbicort); Dr Falk (Budenofalk); Meda (Novolizer)

Examples of information found in this online report include:
- Includes key patent publications for 7 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & READ MORE >

AstraZeneca (Budamax, Entocort, Entocort EC, Pulmicort, Pulmicort Flexhaler, Pulmicort Respules, Pulmicort Turbuhaler, Rhinocort, Rhinocort Aqua, Rhinocort Hayfever, Symbicort); Dr Falk (Budenofalk); Meda (Novolizer)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos